Please select the option that best describes you:

What is your preferred subsequent treatment in patients with metastatic bladder cancer with progression on pembrolizumab/enfortumab?   

In non-FGFR mutated patients, would you use cisplatin/gemcitabine or sacituzimab govitecan at this point?



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Los Angeles VA Medical Center
Thank you, Dr. @Timothy Kuzel. How have you approa...
Medical Oncologist at Northwestern University
This recent development of SG illustrates the risk...
Medical Oncologist at CompHealth
Agree. You can also have HER2 mutations so NGS is...
Sign in or Register to read more